1
|
Magenau J, Jaglowski S, Uberti J, Farag SS, Riwes MM, Pawarode A, Anand S, Ghosh M, Maciejewski J, Braun T, Devenport M, Lu S, Banerjee B, DaSilva C, Devine S, Zhang MJ, Burns LJ, Liu Y, Zheng P, Reddy P. A phase 2 trial of CD24Fc for prevention of graft-versus-host disease. Blood 2024; 143:21-31. [PMID: 37647633 PMCID: PMC10934299 DOI: 10.1182/blood.2023020250] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Revised: 07/25/2023] [Accepted: 08/13/2023] [Indexed: 09/01/2023] Open
Abstract
ABSTRACT Patients who undergo human leukocyte antigen-matched unrelated donor (MUD) allogeneic hematopoietic stem cell transplantation (HSCT) with myeloablative conditioning for hematologic malignancies often develop acute graft-versus-host disease (GVHD) despite standard calcineurin inhibitor-based prophylaxis in combination with methotrexate. This trial evaluated a novel human CD24 fusion protein (CD24Fc/MK-7110) that selectively targets and mitigates inflammation due to damage-associated molecular patterns underlying acute GVHD while preserving protective immunity after myeloablative conditioning. This phase 2a, multicenter study evaluated the pharmacokinetics, safety, and efficacy of CD24Fc in combination with tacrolimus and methotrexate in preventing acute GVHD in adults undergoing MUD HSCT for hematologic malignancies. A double-blind, placebo-controlled, dose-escalation phase to identify a recommended dose was followed by an open-label expansion phase with matched controls to further evaluate the efficacy and safety of CD24Fc in preventing acute GVHD. A multidose regimen of CD24Fc produced sustained drug exposure with similar safety outcomes when compared with single-dose regimens. Grade 3 to 4 acute GVHD-free survival at day 180 was 96.2% (95% confidence interval [CI], 75.7-99.4) in the CD24Fc expansion cohort (CD24Fc multidose), compared with 73.6% (95% CI, 63.2-81.4) in matched controls (hazard ratio, 0.1 [95% CI, 0.0-0.6]; log-rank test, P = .03). No participants in the CD24Fc escalation or expansion phases experienced dose-limiting toxicities (DLTs). The multidose regimen of CD24Fc was well tolerated with no DLTs and was associated with high rates of severe acute GVHD-free survival after myeloablative MUD HSCT. This trial was registered at ClinicalTrials.gov as #NCT02663622.
Collapse
Affiliation(s)
- John Magenau
- Transplantation and Cellular Therapy Program, Rogel Cancer Center, University of Michigan, Ann Arbor, MI
| | - Samantha Jaglowski
- The James Cancer Hospital and Solove Research Institute, Ohio State University, Columbus, OH
| | - Joseph Uberti
- Karmanos Cancer Center, Hudson-Webber Cancer Research Center, Detroit, MI
| | - Sherif S. Farag
- Blood and Bone Marrow Stem Cell Transplant and Immune Cell Therapy Program, Indiana University, Indianapolis, IN
| | - Mary Mansour Riwes
- Transplantation and Cellular Therapy Program, Rogel Cancer Center, University of Michigan, Ann Arbor, MI
| | - Attaphol Pawarode
- Transplantation and Cellular Therapy Program, Rogel Cancer Center, University of Michigan, Ann Arbor, MI
| | - Sarah Anand
- Transplantation and Cellular Therapy Program, Rogel Cancer Center, University of Michigan, Ann Arbor, MI
| | - Monalisa Ghosh
- Transplantation and Cellular Therapy Program, Rogel Cancer Center, University of Michigan, Ann Arbor, MI
| | - John Maciejewski
- Transplantation and Cellular Therapy Program, Rogel Cancer Center, University of Michigan, Ann Arbor, MI
| | - Thomas Braun
- Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI
| | | | | | | | | | | | - Mei-Jie Zhang
- Center for International Blood and Marrow Transplant Research, Milwaukee, WI
| | - Linda J. Burns
- Center for International Blood and Marrow Transplant Research, Milwaukee, WI
| | - Yang Liu
- OncoImmune, Inc, Rockville, MD
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD
| | - Pan Zheng
- OncoImmune, Inc, Rockville, MD
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD
| | - Pavan Reddy
- Transplantation and Cellular Therapy Program, Rogel Cancer Center, University of Michigan, Ann Arbor, MI
| |
Collapse
|
2
|
Vasbinder A, Catalan T, Anderson E, Chu C, Kotzin M, Murphy D, Cheplowitz H, Diaz KM, Bitterman B, Pizzo I, Huang Y, Xie J, Hoeger CW, Kaakati R, Berlin HP, Shadid H, Perry D, Pan M, Takiar R, Padalia K, Mills J, Meloche C, Bardwell A, Rochlen M, Blakely P, Leja M, Banerjee M, Riwes M, Magenau J, Anand S, Ghosh M, Pawarode A, Yanik G, Nathan S, Maciejewski J, Okwuosa T, Hayek SS. Cardiovascular Risk Stratification of Patients Undergoing Hematopoietic Stem Cell Transplantation: The CARE-BMT Risk Score. J Am Heart Assoc 2024; 13:e033599. [PMID: 38158222 PMCID: PMC10863830 DOI: 10.1161/jaha.123.033599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/16/2023] [Accepted: 11/22/2023] [Indexed: 01/03/2024]
Abstract
BACKGROUND Evidence guiding the pre-hematopoietic stem cell transplantation (HSCT) cardiovascular evaluation is limited. We sought to derive and validate a pre-HSCT score for the cardiovascular risk stratification of HSCT candidates. METHODS AND RESULTS We leveraged the CARE-BMT (Cardiovascular Registry in Bone Marrow Transplantation) study, a contemporary multicenter observational study of adult patients who underwent autologous or allogeneic HSCT between 2008 and 2019 (N=2435; mean age at transplant of 55 years; 4.9% Black). We identified the subset of variables most predictive of post-HSCT cardiovascular events, defined as a composite of cardiovascular death, myocardial infarction, heart failure, stroke, atrial fibrillation or flutter, and sustained ventricular tachycardia. We then developed a point-based risk score using the hazard ratios obtained from Cox proportional hazards modeling. The score was externally validated in a separate cohort of 919 HSCT recipients (mean age at transplant 54 years; 20.4% Black). The risk score included age, transplant type, race, coronary artery disease, heart failure, peripheral artery disease, creatinine, triglycerides, and prior anthracycline dose. Risk scores were grouped as low-, intermediate-, and high-risk, with the 5-year cumulative incidence of cardiovascular events being 4.0%, 10.3%, and 22.4%, respectively. The area under the receiver operating curves for predicting cardiovascular events at 100 days, 5 and 10 years post-HSCT were 0.65 (95% CI, 0.59-0.70), 0.73 (95% CI, 0.69-0.76), and 0.76 (95% CI, 0.69-0.81), respectively. The model performed equally well in autologous and allogeneic recipients, as well as in the validation cohort. CONCLUSIONS The CARE-BMT risk score is easy to calculate and could help guide referrals of high-risk HSCT recipients to cardiovascular specialists before transplant and guide long-term monitoring.
Collapse
Affiliation(s)
- Alexi Vasbinder
- Division of Cardiovascular Medicine, Department of Internal MedicineUniversity of MichiganAnn ArborMI
| | - Tonimarie Catalan
- Division of Cardiovascular Medicine, Department of Internal MedicineUniversity of MichiganAnn ArborMI
| | - Elizabeth Anderson
- Division of Cardiovascular Medicine, Department of Internal MedicineUniversity of MichiganAnn ArborMI
| | - Catherine Chu
- Rush University Medical College, Rush UniversityChicagoIL
| | - Megan Kotzin
- Rush University Medical College, Rush UniversityChicagoIL
| | - Danielle Murphy
- Department of PharmacyRush University Medical CenterChicagoIL
| | | | - Kristen Machado Diaz
- Division of Cardiovascular Medicine, Department of Internal MedicineUniversity of MichiganAnn ArborMI
| | - Brayden Bitterman
- Division of Cardiovascular Medicine, Department of Internal MedicineUniversity of MichiganAnn ArborMI
| | - Ian Pizzo
- Division of Cardiovascular Medicine, Department of Internal MedicineUniversity of MichiganAnn ArborMI
| | - Yiyuan Huang
- Department of Biostatistics, School of Public HealthUniversity of MichiganAnn ArborMI
| | - Jeffrey Xie
- Division of Cardiovascular Medicine, Department of Internal MedicineUniversity of MichiganAnn ArborMI
| | - Christopher W. Hoeger
- Division of Cardiology, Department of MedicineBeth Israel Deaconess Medical Center, Harvard Medical SchoolBostonMA
| | - Rayan Kaakati
- Department of Internal MedicineUniversity of MichiganAnn ArborMI
| | - Hanna P. Berlin
- Division of Cardiology, Department of MedicineBeth Israel Deaconess Medical Center, Harvard Medical SchoolBostonMA
| | - Husam Shadid
- Division of Cardiology, Department of MedicineBeth Israel Deaconess Medical Center, Harvard Medical SchoolBostonMA
| | - Daniel Perry
- Division of Cardiovascular Medicine, Department of Internal MedicineUniversity of MichiganAnn ArborMI
| | - Michael Pan
- Division of Cardiology, Department of MedicineBeth Israel Deaconess Medical Center, Harvard Medical SchoolBostonMA
| | - Radhika Takiar
- Division of Hematology/Oncology, Department of Internal MedicineUniversity of MichiganAnn ArborMI
| | - Kishan Padalia
- Division of Cardiology, Department of MedicineBeth Israel Deaconess Medical Center, Harvard Medical SchoolBostonMA
| | - Jamie Mills
- Division of Cardiology, Department of MedicineBeth Israel Deaconess Medical Center, Harvard Medical SchoolBostonMA
| | - Chelsea Meloche
- Division of Cardiovascular MedicineTexas Heart InstituteHoustonTX
| | - Alina Bardwell
- Division of Cardiovascular Medicine, Department of Internal MedicineUniversity of MichiganAnn ArborMI
| | - Matthew Rochlen
- Division of Cardiovascular Medicine, Department of Internal MedicineUniversity of MichiganAnn ArborMI
| | - Pennelope Blakely
- Division of Cardiovascular Medicine, Department of Internal MedicineUniversity of MichiganAnn ArborMI
| | - Monika Leja
- Division of Cardiovascular Medicine, Department of Internal MedicineUniversity of MichiganAnn ArborMI
| | | | - Mary Riwes
- Division of Cardiovascular MedicineTexas Heart InstituteHoustonTX
| | - John Magenau
- Division of Hematology/Oncology, Department of Internal MedicineUniversity of MichiganAnn ArborMI
| | - Sarah Anand
- Division of Hematology/Oncology, Department of Internal MedicineUniversity of MichiganAnn ArborMI
| | - Monalisa Ghosh
- Division of Hematology/Oncology, Department of Internal MedicineUniversity of MichiganAnn ArborMI
| | - Attaphol Pawarode
- Division of Hematology/Oncology, Department of Internal MedicineUniversity of MichiganAnn ArborMI
| | - Gregory Yanik
- Division of Hematology/Oncology, Department of Internal MedicineUniversity of MichiganAnn ArborMI
| | - Sunita Nathan
- Division of Hematology, Oncology and Cell Therapy, Department of Internal MedicineRush University Medical CenterChicagoIL
| | - John Maciejewski
- Division of Hematology/Oncology, Department of Internal MedicineUniversity of MichiganAnn ArborMI
| | - Tochukwu Okwuosa
- Division of Cardiology, Department of Internal MedicineRush University Medical CenterChicagoIL
| | - Salim S. Hayek
- Division of Cardiovascular Medicine, Department of Internal MedicineUniversity of MichiganAnn ArborMI
| |
Collapse
|
3
|
Vasbinder A, Hoeger CW, Catalan T, Anderson E, Chu C, Kotzin M, Xie J, Kaakati R, Berlin HP, Shadid H, Perry D, Pan M, Takiar R, Padalia K, Mills J, Meloche C, Bardwell A, Rochlen M, Blakely P, Leja M, Banerjee M, Riwes M, Magenau J, Anand S, Ghosh M, Pawarode A, Yanik G, Nathan S, Maciejewski J, Okwuosa T, Hayek SS. Cardiovascular Events After Hematopoietic Stem Cell Transplant: Incidence and Risk Factors. JACC CardioOncol 2023; 5:821-832. [PMID: 38205002 PMCID: PMC10774793 DOI: 10.1016/j.jaccao.2023.07.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Accepted: 07/13/2023] [Indexed: 01/12/2024] Open
Abstract
Background Hematopoietic stem cell transplantation (HSCT) is associated with various cardiovascular (CV) complications. Objectives We sought to characterize the incidence and risk factors for short-term and long-term CV events in a contemporary cohort of adult HSCT recipients. Methods We conducted a multicenter observational study of adult patients who underwent autologous or allogeneic HSCT between 2008 and 2019. Data on demographics, clinical characteristics, conditioning regimen, and CV outcomes were collected through chart review. CV outcomes were a composite of CV death, myocardial infarction, heart failure, atrial fibrillation/flutter, stroke, and sustained ventricular tachycardia and were classified as short-term (≤100 days post-HSCT) or long-term (>100 days post-HSCT). Results In 3,354 patients (mean age 55 years; 40.9% female; 30.1% Black) followed for a median time of 2.3 years (Q1-Q3: 1.0-5.4 years), the 100-day and 5-year cumulative incidences of CV events were 4.1% and 13.9%, respectively. Atrial fibrillation/flutter was the most common short- and long-term CV event, with a 100-day incidence of 2.6% and a 5-year incidence of 6.8% followed by heart failure (1.1% at 100 days and 5.4% at 5 years). Allogeneic recipients had a higher incidence of long-term CV events compared to autologous recipients (5-year incidence 16.4% vs 12.1%; P = 0.002). Baseline CV comorbidities were associated with a higher risk of long-term CV events. Conclusions The incidence of short-term CV events in HSCT recipients is relatively low. Long-term events were more common among allogeneic recipients and those with pre-existing CV comorbidities.
Collapse
Affiliation(s)
- Alexi Vasbinder
- Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Christopher W. Hoeger
- Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
| | - Tonimarie Catalan
- Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Elizabeth Anderson
- Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Catherine Chu
- Rush Medical College, Rush University, Chicago, Illinois, USA
| | - Megan Kotzin
- Rush Medical College, Rush University, Chicago, Illinois, USA
| | - Jeffrey Xie
- Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Rayan Kaakati
- Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Hanna P. Berlin
- Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Husam Shadid
- Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Daniel Perry
- Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Michael Pan
- Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Radhika Takiar
- Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Kishan Padalia
- Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Jamie Mills
- Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Chelsea Meloche
- Division of Cardiovascular Medicine, Texas Heart Institute, Houston, Texas, USA
| | - Alina Bardwell
- Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Matthew Rochlen
- Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Pennelope Blakely
- Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Monika Leja
- Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Mousumi Banerjee
- Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA
| | - Mary Riwes
- Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - John Magenau
- Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Sarah Anand
- Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Monalisa Ghosh
- Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Attaphol Pawarode
- Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Gregory Yanik
- Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Sunita Nathan
- Division of Hematology, Oncology and Cell Therapy, Department of Internal Medicine, Rush Medical College, Chicago, Illinois, USA
| | - John Maciejewski
- Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Tochukwu Okwuosa
- Division of Cardiology, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA
| | - Salim S. Hayek
- Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| |
Collapse
|
4
|
Riwes MM, Golob JL, Magenau J, Shan M, Dick G, Braun T, Schmidt TM, Pawarode A, Anand S, Ghosh M, Maciejewski J, King D, Choi S, Yanik G, Geer M, Hillman E, Lyssiotis CA, Tewari M, Reddy P. Feasibility of a dietary intervention to modify gut microbial metabolism in patients with hematopoietic stem cell transplantation. Nat Med 2023; 29:2805-2813. [PMID: 37857710 PMCID: PMC10667101 DOI: 10.1038/s41591-023-02587-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Accepted: 09/12/2023] [Indexed: 10/21/2023]
Abstract
Evaluation of the impact of dietary intervention on gastrointestinal microbiota and metabolites after allogeneic hematopoietic stem cell transplantation (HCT) is lacking. We conducted a feasibility study as the first of a two-phase trial. Ten adults received resistant potato starch (RPS) daily from day -7 to day 100. The primary objective was to test the feasibility of RPS and its effect on intestinal microbiome and metabolites, including the short-chain fatty acid butyrate. Feasibility met the preset goal of 60% or more, adhering to 70% or more doses; fecal butyrate levels were significantly higher when participants were on RPS than when they were not (P < 0.0001). An exploratory objective was to evaluate plasma metabolites. We observed longitudinal changes in plasma metabolites compared to baseline, which were independent of RPS (P < 0.0001). However, in recipients of RPS, the dominant plasma metabolites were more stable compared to historical controls with significant difference at engraftment (P < 0.05). These results indicate that RPS in recipients of allogeneic HCT is feasible; in this study, it was associated with significant alterations in intestinal and plasma metabolites. A phase 2 trial examining the effect of RPS on graft-versus-host disease in recipients of allogeneic HCT is underway. ClinicalTrials.gov registration: NCT02763033 .
Collapse
Affiliation(s)
- Mary M Riwes
- Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Rogel Cancer Center, Ann Arbor, MI, USA.
| | - Jonathan L Golob
- Department of Internal Medicine, Division of Infectious Disease, University of Michigan, Ann Arbor, MI, USA
| | - John Magenau
- Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Rogel Cancer Center, Ann Arbor, MI, USA
| | - Mengrou Shan
- Department of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, MI, USA
| | - Gregory Dick
- Department of Earth & Environmental Sciences, University of Michigan, Ann Arbor, MI, USA
| | - Thomas Braun
- Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA
| | - Thomas M Schmidt
- Department of Internal Medicine, Division of Infectious Disease, University of Michigan, Ann Arbor, MI, USA
| | - Attaphol Pawarode
- Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Rogel Cancer Center, Ann Arbor, MI, USA
| | - Sarah Anand
- Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Rogel Cancer Center, Ann Arbor, MI, USA
| | - Monalisa Ghosh
- Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Rogel Cancer Center, Ann Arbor, MI, USA
| | - John Maciejewski
- Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Rogel Cancer Center, Ann Arbor, MI, USA
| | - Darren King
- Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Rogel Cancer Center, Ann Arbor, MI, USA
| | - Sung Choi
- Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Rogel Cancer Center, Ann Arbor, MI, USA
| | - Gregory Yanik
- Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Rogel Cancer Center, Ann Arbor, MI, USA
| | - Marcus Geer
- Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Rogel Cancer Center, Ann Arbor, MI, USA
| | - Ethan Hillman
- Department of Internal Medicine, Division of Infectious Disease, University of Michigan, Ann Arbor, MI, USA
| | - Costas A Lyssiotis
- Department of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, MI, USA
| | - Muneesh Tewari
- Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Rogel Cancer Center, Ann Arbor, MI, USA
| | - Pavan Reddy
- Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Rogel Cancer Center, Ann Arbor, MI, USA.
- Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
| |
Collapse
|
5
|
Coda J, Raser K, Ghosh M, Gregg K, Maciejewski J, Pawarode A, Riwes MM, Tillman C, Yanik GA, Magenau J, Pianko M. Pneumocystis Jirovecii Infection in Autologous Hematopoietic Stem Cell Transplant Recipients. Transplant Cell Ther 2022. [DOI: 10.1016/s2666-6367(22)00644-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
6
|
Vuong W, Ganguly S, Balyimez A, Halima A, Kerr C, Lee B, Klein E, Day M, Tomlins S, Gupta S, Ornstein M, Tendulkar R, Stephans K, Ciezki J, Grivas P, Maciejewski J, Jha B, Mian O. Identification of Putative Gene-Target Modulators of Radiosensitivity in Bladder Cancer Cell Lines (BlaCCL). Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.850] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
7
|
Pagliuca S, Gurnari C, Hong S, Kongkiatkamon S, Awada H, Terkawi L, Zawit M, Visconte V, Hamilton B, Carraway H, Majhail N, Maciejewski J. Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation. Leuk Res 2021. [DOI: 10.1016/j.leukres.2021.106678.3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
8
|
Makishima H, Nannya Y, Momozawa Y, Gurnari C, Kulasekararaj A, Yoshizato T, Takeda J, Atsuta Y, Shiozawa Y, Iijima-Yamashita Y, Saiki R, Yoshida K, Shiraishi Y, Nagata Y, Onizuka M, Nakagawa M, Itonaga H, Kanda Y, Miyazaki Y, Sanada M, Tsurumi H, Kasahara S, Kondo-Takaori A, Ohyashiki K, Kiguchi T, Matsuda F, Jansen J, Papaemmanuil E, Creignou M, Tobiasson M, Hellström-Lindberg E, Polprasert C, Malcovati L, Cazzola M, Haferlach T, Maciejewski J, Kamatani Y, Miyano S, Ogawa S. Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution. Leuk Res 2021. [DOI: 10.1016/j.leukres.2021.106679.5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
9
|
Gurnari C, Pagliuca S, Patel B, Awada H, Shen W, Kongkiatkamon S, Terkawi L, Zawit M, Visconte V, Corey S, Voso M, Carraway H, Maciejewski J. Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations. Leuk Res 2021. [DOI: 10.1016/j.leukres.2021.106678.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
10
|
Adema V, Kanagal-Shamanna R, Ma F, Yang H, Ganan-Gomez I, Santoni A, Thongon N, Montalban-Bravo G, Pellegrini M, Bueso-Ramos C, Maciejewski J, Visconte V, Carew J, Garcia-Manero G, Colla S. Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations. Leuk Res 2021. [DOI: 10.1016/j.leukres.2021.106678.4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
11
|
Gurnari C, Pagliuca S, Guan Y, Adema V, Hershberger C, Ni Y, Awada H, Kongkiatkamon S, Zawit M, Coutinho D, Zalcberg I, Ahn JS, Kim HJ, Kim D, Minden M, Jansen J, Meggendorfer M, Haferlach C, Jha B, Haferlach T, Maciejewski J, Visconte V. Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling. Leuk Res 2021. [DOI: 10.1016/j.leukres.2021.106680.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
12
|
Vuong W, Balyimez A, Ganguly S, Laximi S, Kerr C, Lee B, Klein E, Day M, Tomlins S, Gupta S, Ornstein M, Tendulkar R, Stephans K, Ciezki J, Grivas P, Maciejewski J, Jha B, Mian O. Transcriptomic and Mutational Analyses Identify Biological Processes Correlated with Bladder Cancer Cell Line (BlaCCL) Radiation Response. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.1759] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
13
|
Zheng P, Liu Y, Chen H, Devenport M, Reddy P, Farag SS, Devine SM, Jaglowski S, Uberti J, Braun T, Yanik GA, Choi S, Riwes MM, Maciejewski J, Pawarode A, Anand S, Ghosh M, Magenau JM. Targeting Danger Associated Molecular Pattern (DAMP) with CD24Fc to Reduce Acute Gvhd: Study Design on a Randomized Double Blind Placebo Controlled Phase III Clinical Trial (CATHY Study). Biol Blood Marrow Transplant 2020. [DOI: 10.1016/j.bbmt.2019.12.741] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
14
|
Magenau JM, Jaglowski S, Farag SS, Uberti J, Pawarode A, Riwes MM, Braun T, Ghosh M, Anand S, Maciejewski J, Yanik GA, Choi S, Zheng P, Liu Y, Devine SM, Reddy P. Mitigating Damage Response with CD24 Fusion Protein for Prevention of Acute Graft-Versus-Host Disease. Biol Blood Marrow Transplant 2020. [DOI: 10.1016/j.bbmt.2019.12.126] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
15
|
Seddon AN, Laul A, Yadav U, Schultz K, Maciejewski J, Nathan S. Alternative Conditioning Regimens Incorporating Bortezomib (Bor) or Carmustine (car) with High-Dose Melphalan (HDM) are Safe and Effective for Multiple Myeloma Patients (pts) Receiving a Second Autologous Stem Cell Transplant (AutoSCT). Biol Blood Marrow Transplant 2018. [DOI: 10.1016/j.bbmt.2017.12.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
16
|
Kurbegovic-Skaljic I, Piggott SC, Basu S, Nathan S, Maciejewski J, Merchant N, Prod MH, Kanangat S. P188 The effect of killer immunoglobulin-like receptor genes on clinical outcome after hematopoietic stem cell transplantation. Hum Immunol 2017. [DOI: 10.1016/j.humimm.2017.06.248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
17
|
Radivoyevitch T, Kuzmanovic T, Sanikommu S, Hirsch C, Abdel-Hamid O, Przychodzen B, Clemente M, Jha B, Lindner D, Moolenaar R, Xu M, Mukherjee S, Sekeres M, Maciejewski J. Myeloid Cancer Mutation Rates Depend on Prior Cancer Therapies. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30168-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
18
|
Hurtado A, Luengo-Gil G, Chen-Liang T, Palomo L, Lumbreras E, Przychodzen B, Amigo M, Díez-Campelo M, Zamora L, Ortuño F, Vicente V, Maciejewski J, del Cañizo C, Solé F, Ferrer-Marín F, Jerez A. DNA Repair Genes Transcriptome in Chronic Myelomonocytic Leukemia. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30276-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
19
|
Jha B, Phillips J, Hasipek M, Tiwari A, Radivoyevitch T, Maciejewski J. Targeting the Oncogenic Nexus of SETBP1-Set-PP2A by Structure Guided Small Molecule Design and Fragment Based Chemical Synthesis. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30315-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
20
|
Jha B, Al-harbi S, Hasipek M, Tiwari A, Phillips J, Radivoyevitch T, Maciejewski J. Targeting the Oncogenic Node of Hedgehog Signaling in MDS. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30314-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
21
|
Nagata Y, Makishima H, Radivoyevitch T, Hirsch C, Przychodzen B, Kuzmanovic T, Li S, Yoshida K, Suzuki H, Adema V, Clemente M, Shiraishi Y, Chiba K, Tanaka H, Sole F, Miyano S, Sekeres M, LaFramboise T, Ogawa S, Maciejewski J. Ancestral Events Including Germline and Somatic Mutations Determine Subclonal Events and Affect Phenotype of Progression in MDS. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30127-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
22
|
Molenaar R, Pleyer C, Radivoyevitch T, Carraway H, Kalaycio M, Maciejewski J, Sekeres M, Mukherjee S. Increased Risk of Developing Myeloid Neoplasms, Including Myelodysplastic Syndrome, in Well-Differentiated Thyroid Cancers Treated with Radioactive Iodine. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30255-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
23
|
Visconte V, Adema V, Hirbawi Y, Przychodzen B, Kelly K, Hirsch C, Clemente M, Balasubramanian S, Carraway H, Lindner D, Sekeres M, Rogers H, Phillips J, Radivoyevitch T, Nawrocki S, Carew J, Maciejewski J. Autophagy Stimulation Improves Erythroid Proliferative Capacity in Models of SF3B1 Mutant MDS. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30166-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
24
|
Radivoyevitch T, Millard H, Shaw B, Brazauskas R, Savani B, Flowers M, Battiwalla M, Hamilton B, Sekeres M, Maciejewski J, Litzow M, Gale R, Dean R, Hashmi S. Autotransplants for Lymphoid Neoplasms Increase the Risks of MDS More Than AML. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30404-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
25
|
Nazha A, Al-Issa K, Zarzour A, Radivoyevitch T, Hamilton B, Gerds A, Mukherjee S, Adema V, Clemente M, Patel B, Hirsch C, Advani A, Bartlomiej P, Carraway H, Maciejewski J, Sekeres M. Adding Molecular Data to Prognostic Models can Improve their Predictive Power in Treated Patients with Myelodysplastic Syndromes (MDS). Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30163-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
26
|
Radivoyevitch T, Hirsch C, Adema V, Jha B, Lindner D, Olinski R, Xu M, Maciejewski J, Visconte V. TET2 is Iron-Dependent so its Activity may be Compromised in SF3B1 Mutated Age-Related Clonal Hematopoiesis of Indeterminate Potential. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30148-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
27
|
Della Porta MG, Tuechler H, Malcovati L, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SMM, Miyazaki Y, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL, Cazzola M. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia 2015; 29:1502-13. [PMID: 25721895 DOI: 10.1038/leu.2015.55] [Citation(s) in RCA: 89] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2015] [Revised: 02/10/2015] [Accepted: 02/16/2015] [Indexed: 02/03/2023]
Abstract
A risk-adapted treatment strategy is mandatory for myelodysplastic syndromes (MDS). We refined the World Health Organization (WHO)-classification-based Prognostic Scoring System (WPSS) by determining the impact of the newer clinical and cytogenetic features, and we compared its prognostic power to that of the revised International Prognostic Scoring System (IPSS-R). A population of 5326 untreated MDS was considered. We analyzed single WPSS parameters and confirmed that the WHO classification and severe anemia provide important prognostic information in MDS. A strong correlation was found between the WPSS including the new cytogenetic risk stratification and WPSS adopting original criteria. We then compared WPSS with the IPSS-R prognostic system. A highly significant correlation was found between the WPSS and IPSS-R risk classifications. Discrepancies did occur among lower-risk patients in whom the number of dysplastic hematopoietic lineages as assessed by morphology did not reflect the severity of peripheral blood cytopenias and/or increased marrow blast count. Moreover, severe anemia has higher prognostic weight in the WPSS versus IPSS-R model. Overall, both systems well represent the prognostic risk of MDS patients defined by WHO morphologic criteria. This study provides relevant in formation for the implementation of risk-adapted strategies in MDS.
Collapse
Affiliation(s)
- M G Della Porta
- 1] Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy [2] Department of Internal Medicine, University of Pavia, Pavia, Italy
| | - H Tuechler
- Hanusch Hospital, Boltzmann Institute for Leukemia Research, Vienna, Austria
| | - L Malcovati
- 1] Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy [2] Department of Molecular Medicine, University of Pavia, Pavia, Italy
| | - J Schanz
- Georg August Universität, Göttingen, Germany
| | - G Sanz
- Hospital Universitario La Fe, Valencia, Spain
| | - G Garcia-Manero
- The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| | - F Solé
- Institut de Recerca contra la Leucèmia Josep Carreras, Barcelona, Spain
| | - J M Bennett
- James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA
| | - D Bowen
- St James's University Hospital, Leeds, UK
| | - P Fenaux
- Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP)/University Paris XIII, Bobigny, France
| | - F Dreyfus
- Hôpital Cochin, AP-HP University of Paris V, Paris, France
| | - H Kantarjian
- The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| | - A Kuendgen
- Heinrich-Heine University Hospital, Düsseldorf, Germany
| | - A Levis
- Fondazione Italiana Sindromi Mielodisplastiche c/o SS Antonio e Biagio Hospital, Alessandria, Italy
| | - J Cermak
- Institute of Hematology and Blood Transfusion, Praha, Czech Republic
| | - C Fonatsch
- Medical University of Vienna, Vienna, Austria
| | - M M Le Beau
- University of Chicago Comprehensive Cancer Research Center, Chicago, IL, USA
| | - M L Slovak
- Quest Diagnostics Nichols Institute, Chantilly, VA, USA
| | - O Krieger
- Elisabethinen Hospital, Linz, Austria
| | - M Luebbert
- University of Freiburg Medical Center, Freiburg, Germany
| | | | | | - Y Miyazaki
- Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - M Pfeilstöcker
- Hanusch Hospital and L. Boltzmann Cluster Oncology, Vienna, Austria
| | | | - W R Sperr
- Medical University of Vienna, Vienna, Austria
| | - R Stauder
- Hanusch Hospital and L. Boltzmann Cluster Oncology, Vienna, Austria
| | - S Tauro
- University of Dundee, Dundee, Scotland, UK
| | - P Valent
- Medical University of Vienna, Vienna, Austria
| | - T Vallespi
- Hospital Universitario Vall d'Hebron, Barcelona, Spain
| | | | - U Germing
- Heinrich-Heine University Hospital, Düsseldorf, Germany
| | - D Haase
- Georg August Universität, Göttingen, Germany
| | - P L Greenberg
- Division of Hematology, Stanford University Cancer Center, Stanford, CA, USA
| | - M Cazzola
- 1] Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy [2] Department of Molecular Medicine, University of Pavia, Pavia, Italy
| |
Collapse
|
28
|
Nazha A, Radivoyevitch T, Thota S, Makishima H, Patel B, Seastone D, Carraway H, Carew J, Przychodzen B, Kalaycio M, Sekeres M, Maciejewski J. 20 SOMATIC MUTATIONAL MODEL TO PREDICT RESPONSE TO HYPOMETHYLATING AGENTS IN MYELODYSPLASTIC SYNDROMES. Leuk Res 2015. [DOI: 10.1016/s0145-2126(15)30021-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
29
|
Negoro E, Hosono N, Shen W, Przychozen B, Patel B, Tetsuichi Y, Brittney D, Cassandra H, Polprasert C, Clemente M, Sekeres M, Ogawa S, Makishima H, Maciejewski J. 66 SUBCLINICAL ANCESTRAL EVENTS FOR PROGRESSION TO MANIFEST CLONAL MYELODYSPLASIA ARE PRESENT IN APLASTIC ANEMIA AT PRESENTATION: COMPARISON OF DE NOVO AND POST AA MDS. Leuk Res 2015. [DOI: 10.1016/s0145-2126(15)30067-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
30
|
Makishima H, Yoshida K, Przychodzen B, Swapna T, Patel B, Nagata Y, Miyano S, Sekeres M, Shih L, Ogawa S, Maciejewski J. 270 FOUNDER AND SUBCLONAL SOMATIC MUTATIONS CONTRIBUTING TO LEUKEMIC EVOLUTION IN MYELODYSPLASTIC SYNDROMES AND RELATED MYELOID NEOPLASMS. Leuk Res 2015. [DOI: 10.1016/s0145-2126(15)30271-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
31
|
Steensma D, Abedi M, Bejar R, Cogle C, Foucar K, Garcia-Manero G, George T, Grinblatt D, Komrokji R, Maciejewski J, Pollyea D, Roboz G, Savona M, Scott B, Sekeres M, Thompson M, Sugrue M, Swern A, Nifenecker M, Erba H. 249 CONNECT MDS AND AML: THE MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA (AML) DISEASE REGISTRY. Leuk Res 2015. [DOI: 10.1016/s0145-2126(15)30250-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
32
|
Nathan S, Jimenez AM, Moreno AD, Maciejewski J, Fung HC. Severe Mucositis with Bendamustine Etoposide Ara-C and Melphalan (Be-EAM) As Conditioning Regimen in Non-Hodgkin Lymphoma (NHL) Patients Undergoing Autologous Stem Cell Transplantation (AutoSCT). Biol Blood Marrow Transplant 2015. [DOI: 10.1016/j.bbmt.2014.11.200] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
33
|
Jimenez AM, Moreno AD, Maciejewski J, Dalovisio A, Katz D, Havey C, Merchant N, Fung HC, Nathan S. Graft Versus Host Disease Prophylaxis with a Bortezomib-Based Regimen without G-CSF Support for Patients Undergoing MUD Transplant: Evaluation of Engraftment Kinetics and Transplant Outcomes. Biol Blood Marrow Transplant 2015. [DOI: 10.1016/j.bbmt.2014.11.463] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
34
|
Hobfoll SE, Gerhart JI, Zalta AK, Wells K, Maciejewski J, Fung H. Posttraumatic stress symptoms predict impaired neutrophil recovery in stem cell transplant recipients. Psychooncology 2015; 24:1529-35. [PMID: 25628257 DOI: 10.1002/pon.3761] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2014] [Revised: 12/15/2014] [Accepted: 12/23/2014] [Indexed: 11/07/2022]
Abstract
OBJECTIVE Despite the potentially life-saving effects of stem cell transplant (SCT), many transplant patients experience traumatic stress reactions due to mortality threat, interpersonal isolation, financial and occupational loss, and invasive medical procedures. Emerging evidence suggests that trauma-related stress symptoms (TSS) predict significant health complications following SCT. The aim of the current prospective study was to examine TSS in the acute aftermath of SCT as a predictor of neutrophil recovery following SCT, a crucial component of immune defense against infection. METHODS Fifty-one autologous SCT recipients were assessed for TSS 7 days after SCT. Patients' absolute neutrophil counts were collected from medical charts for the first 30 days following SCT. Hierarchical linear growth modeling was used to test the hypothesis that TSS at day 7 would be associated with delayed recovery of neutrophil counts from days 9 to 30 post SCT, that is, when neutrophil counts began to recover. RESULTS As hypothesized, TSS measured 7 days after SCT was significantly associated with slower neutrophil recovery even after pre-existing TSS, depression, distress related to physical symptoms, and potential medical confounds were statistically controlled. Exploratory analyses showed that of the TSS symptom clusters, re-experiencing symptoms and hyperarousal symptoms predicted neutrophil recovery, whereas avoidance symptoms did not. CONCLUSION Though traumatic stress symptoms may be a normative response to SCT, our findings suggest that TSS following SCT may interfere with neutrophil recovery and overall health. These results provide further insight as to potential mechanisms by which traumatic stress translates to poor medical outcomes for SCT patients.
Collapse
Affiliation(s)
- Stevan E Hobfoll
- Department of Behavioral Sciences, Rush University Medical Center, Chicago, IL, USA
| | - James I Gerhart
- Department of Behavioral Sciences, Rush University Medical Center, Chicago, IL, USA
| | - Alyson K Zalta
- Department of Behavioral Sciences, Rush University Medical Center, Chicago, IL, USA.,Department of Psychiatry, Rush University Medical Center, Chicago, IL, USA
| | - Kurrie Wells
- Cancer Treatment Centers of America, Philadelphia, PA, USA
| | - John Maciejewski
- The Coleman Foundation Blood and Bone Marrow Transplant Program, Rush University Medical Center, Chicago, IL, USA
| | - Henry Fung
- Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
| |
Collapse
|
35
|
Chambreau SD, Schenk AC, Sheppard AJ, Yandek GR, Vaghjiani GL, Maciejewski J, Koh CJ, Golan A, Leone SR. Thermal Decomposition Mechanisms of Alkylimidazolium Ionic Liquids with Cyano-Functionalized Anions. J Phys Chem A 2014; 118:11119-32. [DOI: 10.1021/jp5095855] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Steven D. Chambreau
- ERC,
Inc., and ‡Propellants Branch, Aerospace Systems Directorate, Air Force Research Laboratory, AFRL/RQRP, Edwards Air Force Base, California 93524, United States
| | | | | | | | | | - John Maciejewski
- Department
of Chemistry, University of Idaho, Moscow, Idaho 83844, United States
| | - Christine J. Koh
- Departments
of Chemistry and Physics, University of California, Berkeley, California 94720, United States
| | - Amir Golan
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States
| | - Stephen R. Leone
- Departments
of Chemistry and Physics, University of California, Berkeley, California 94720, United States
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States
| |
Collapse
|
36
|
Sheean PM, Kilkus JM, Liu D, Maciejewski J, Braunschweig CA. Incident hyperglycemia, parenteral nutrition administration and adverse outcomes in patients with myeloma admitted for initial auto-SCT. Bone Marrow Transplant 2013; 48:1117-22. [PMID: 23419432 PMCID: PMC3661701 DOI: 10.1038/bmt.2013.11] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2012] [Revised: 01/02/2013] [Accepted: 01/07/2013] [Indexed: 12/22/2022]
Abstract
Parenteral nutrition (PN) exacerbates hyperglycemia, which is associated with increased morbidity and mortality in various cancer populations. By using a retrospective design, we examined incident hyperglycemia in PN and non-PN recipients and the associations with clinical events and 5-year survival in a cohort treated for myeloma with melphalan and auto-SCT (n=112). Clinical comparisons were made at admission, and 'before' and 'after' initiating PN to discern differences and temporality. Actual infusion times were used for PN patients; time frames based on mean PN infusion days were created for the non-PN recipients. Oral intake was lower 'before' in PN vs non-PN patients (P<0.001); however, no differences in mucositis, emesis, infections or transfusions were detected 'before.' Incident hyperglycemia (≥7.0 mmol/L) was significant 'after' PN initiation, and PN recipients experienced delays in WBC (P<0.05) and platelet engraftment (P=0.009), and required significantly greater RBC (P=0.0014) and platelet (P=0.001) support 'after' than non-PN patients. Neutropenic fever and longer hospital stay were more frequent among PN vs non-PN recipients (P<0.001). Differences in 5-year mortality were not apparent. The findings fail to support clinical benefits of PN administration during auto-SCT for myeloma. Further study is needed to discern if hyperglycemia or feeding per se was deleterious in this patient population.
Collapse
Affiliation(s)
- Patricia M. Sheean
- Post-doctoral Research Associate, University of Illinois at Chicago, Institute for Health Policy and Research, M/C 275, 1747 West Roosevelt Road, Chicago, IL 60608; , Phone: 312-413-1793, Fax: 312-996-2703
| | - Jennifer M. Kilkus
- General Clinical Research Center, The University of Chicago Hospitals, 5841 S. Maryland Ave., Chicago, IL 60637;
| | - Dishan Liu
- University of Illinois at Chicago, Institute for Health Research and Policy, M/C 275, 1747 West Roosevelt Road, Chicago, IL 60608;
| | - John Maciejewski
- Rush University Medical Center, Department of Medicine, Section of Hematology, 1650 W. Harrison Street, Chicago, IL 60612;
| | - Carol A. Braunschweig
- University of Illinois at Chicago, Department of Kinesiology and Nutrition, 1919 W. Taylor, Room 650, Chicago, IL 60612;
| |
Collapse
|
37
|
Sekeres M, Ades L, Tuechler H, Sanz G, Levis A, Malcovati L, Cazzola M, Magalhães S, Luebbert M, Haase D, Schanz J, Cermak J, Garcia-Manero G, Sole F, Benett J, Bowen D, Dreyfus F, Kantarjian H, Kuendgen A, Fonatsch C, Le Beau M, Slovak M, Krieger O, Maciejewski J, Miyazaki Y, Pfeilstoecker M, Sperr W, Stauder R, Tauro S, Valent P, Vallespi T, Van de Loosdrecht A, Germing U, Fenaux P, Greenberg P. P-113 Revised International Prognostic Scoring System (IPSS-R) for primary treated myelodysplastic syndromes (MDS) patients: A report from the IWG-PM. Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70161-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
38
|
Nathan S, Maciejewski J, Rich E, Karmali R, Venugopal P, Gregory SA, Fung HC. Stem Cell Mobilization Using the Combination of GCSF (G) and Plerixafor (P) for Lymphoma Patients (pts) Can Overcome the Poor Prognostic Factors That Impact Mobilization Per GITMO Criteria. Biol Blood Marrow Transplant 2013. [DOI: 10.1016/j.bbmt.2012.11.301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
39
|
Clark JM, Kelley B, Titze J, Fung H, Maciejewski J, Nathan S, Rich E, Basu S, Kaufman HL. Clinical and Safety Profile of High-Dose Interleukin-2 Treatment in Elderly Patients with Metastatic Melanoma and Renal Cell Carcinoma. Oncology 2013; 84:123-6. [DOI: 10.1159/000342764] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2012] [Accepted: 07/05/2012] [Indexed: 11/19/2022]
|
40
|
Yang L, Mailloux A, Rollison DE, Painter JS, Maciejewski J, Paquette RL, Loughran TP, McGraw K, Makishima H, Radhakrishnan R, Wei S, Ren X, Komrokji R, List AF, Epling-Burnette PK. Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency. Leukemia 2012; 27:897-906. [PMID: 23072779 PMCID: PMC4346223 DOI: 10.1038/leu.2012.300] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Telomeres are specialized structures providing chromosome integrity during cellular division along with protection against premature senescence and apoptosis. Accelerated telomere attrition in patients with myelodysplastic syndrome (MDS) occurs by an undefined mechanism. Although the MDS clone originates within the myeloid compartment, T-lymphocytes display repertoire contraction and loss of naive T-cells. The replicative lifespan of T-cells is stringently regulated by telomerase activity. In MDS cases, we show that purified CD3+ T-cells have significantly shorter telomere length and reduced proliferative capacity upon stimulation compared with controls. To understand the mechanism, telomerase enzymatic activity and telomerase reverse transcriptase (hTERT), gene expression were compared in MDS cases (n=35) and healthy controls (n=42) within different T-cell compartments. Telomerase activity is greatest in naive T-cells illustrating the importance of telomere repair in homeostatic repertoire regulation. Compared with healthy controls, MDS cases had lower telomerase induction (P<0.0001) that correlated with significantly lower hTERT mRNA (P<0.0001), independent of age and disease stratification. hTERT mRNA deficiency affected naive but not memory T-cells, and telomere erosion in MDS occurred without evidence of an hTERT-promoter mutation, copy number variation or deletion. Telomerase insufficiency may undermine homeostatic control within the hematopoietic compartment and promote a change in the T-cell repertoire in MDS.
Collapse
Affiliation(s)
- L Yang
- Immunology Program at the H Lee Moffitt Cancer Center, Tampa, FL, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Andersson E, Eldfors S, Koskela H, Ellonen P, Kallioniemi O, Porkka K, Loughran T, Maciejewski J, Heckman C, Mustjoki S. 825 Exome Sequencing of T-LGL Leukemia Patient Revealed ANGPT2 as a Possible Mutational Target. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71458-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
42
|
Ratajczak J, Kucia M, Mierzejewska K, Liu R, Kim CH, Natarajan N, Sharma V, Miller DM, Maciejewski J, Ratajczak MZ. A novel view of paroxysmal nocturnal hemoglobinuria pathogenesis: more motile PNH hematopoietic stem/progenitor cells displace normal HSPCs from their niches in bone marrow due to defective adhesion, enhanced migration and mobilization in response to erythrocyte-released sphingosine-1 phosphate gradient. Leukemia 2012; 26:1722-5. [PMID: 22343521 DOI: 10.1038/leu.2012.46] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
43
|
Jimenez A, Rich E, Nathan S, Maciejewski J, Shammo J, Katz D, Braun E, Hashmi S, Fung H. Blast Percentage Prior to Transplantation Is the Strongest Predictive Factor for Survival After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in Patients with Myelodysplastic Syndrome (MDS). Biol Blood Marrow Transplant 2012. [DOI: 10.1016/j.bbmt.2011.12.379] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
44
|
Germing U, Lauseker M, Hildebrandt B, Symeonidis A, Cermak J, Fenaux P, Kelaidi C, Pfeilstöcker M, Nösslinger T, Sekeres M, Maciejewski J, Haase D, Schanz J, Seymour J, Kenealy M, Weide R, Lübbert M, Platzbecker U, Valent P, Götze K, Stauder R, Blum S, Kreuzer KA, Schlenk R, Ganser A, Hofmann WK, Aul C, Krieger O, Kündgen A, Haas R, Hasford J, Giagounidis A. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study. Leukemia 2012; 26:1286-92. [PMID: 22289990 DOI: 10.1038/leu.2011.391] [Citation(s) in RCA: 96] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
45
|
Negrotto S, Ng KP, Jankowska AM, Bodo J, Gopalan B, Guinta K, Mulloy JC, Hsi E, Maciejewski J, Saunthararajah Y. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors. Leukemia 2011; 26:244-54. [PMID: 21836612 PMCID: PMC3217177 DOI: 10.1038/leu.2011.207] [Citation(s) in RCA: 68] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
The DNA hypomethylating drug decitabine maintains normal hematopoietic stem cell (HSC) self-renewal but induces terminal differentiation in acute myeloid leukemia (AML) cells. The basis for these contrasting cell-fates, and for selective CpG hypomethylation by decitabine, is poorly understood. Promoter CpGs, with methylation measured by microarray, were classified by the direction of methylation change with normal myeloid maturation. In AML cells, the methylation pattern at maturation-responsive CpG suggested at least partial maturation. Consistent with partial maturation, in gene expression analyses, AML cells expressed high levels of the key lineage-specifying factor CEBPA, but relatively low levels of the key late-differentiation driver CEBPE. In methylation analysis by mass-spectrometry, CEBPE promoter CpG that are usually hypomethylated during granulocyte maturation were significantly hypermethylated in AML cells. Decitabine treatment induced cellular differentiation of AML cells, and the largest methylation decreases were at CpG that are hypomethylated with myeloid maturation, including CEBPE promoter CpG. In contrast, decitabine-treated normal HSC retained immature morphology, and methylation significantly decreased at CpG that are less methylated in immature cells. High expression of lineage-specifying factor and aberrant epigenetic repression of some key late-differentiation genes distinguishes AML cells from normal HSC and could explain the contrasting differentiation and methylation responses to decitabine.
Collapse
Affiliation(s)
- S Negrotto
- Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Greenberg P, Tuechler H, Schanz J, Sole F, Bennett J, Garcia-Manero G, Levis A, Malcovati L, Cazzola M, Sanz G, Cermak J, Fonatsch C, LeBeau M, Slovak M, Krieger O, Luebbert M, Magalhaes S, Miyazaki Y, Pfeilstocker M, Sekeres M, Maciejewski J, Stauder R, Tauro S, van de Loosdrecht A, Germing U, Fenaux P, Haase D. 14 Revised International Prognostic Scoring System (IPSS-R), developed by the International Prognostic Working Group for Prognosis in MDS (IWG-PM). Leuk Res 2011. [DOI: 10.1016/s0145-2126(11)70016-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
47
|
Jimenez A, Vasoo S, Maciejewski J, Rich E, Karmali R, Venugopal P, Gregory S, Fung H, Nathan S. Neutropenic Enterocolitis (NE) in Adult Patients (PTS) Undergoing Hematopoietic Stem Cell Transplant (HSCT): Impact of Bowel Wall Thickness on Clinical Outcomes. Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
48
|
Nathan S, Jimenez A, Maciejewski J, Rich E, Lo M, Schultz K, Fung H. High Incidence of Hyperacute GVHD (HaGVHD) in Patients (pts) Undergoing Unrelated Donor Allogeneic Hematopoeitic Stem Cell Transplantation (URalloHSCT) Receiving a Non-Methotrexate (Non-MTX) Containing Regimen. Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
49
|
Zhang A, Pidwell D, Ball E, Zou Y, Viny A, Thomas D, Kawczak P, Jurcago R, Eilrich H, Maciejewski J, Stastny P, Askar M. 161-P: Two novel MICA alleles: MICA*00203 and MICA*058. Hum Immunol 2009. [DOI: 10.1016/j.humimm.2009.09.194] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
50
|
Zierhoffer S, Wójtowicz J, Maciejewski J, Walczak M. Nierenangiographie bei Gonadendysgenesie. ROFO-FORTSCHR RONTG 2009. [DOI: 10.1055/s-0029-1228280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|